Proteolytic bacteria expansion during colitis amplifies inflammation through cleavage of the external domain of PAR2

Gut Microbes. 2024 Jan-Dec;16(1):2387857. doi: 10.1080/19490976.2024.2387857. Epub 2024 Aug 22.

Abstract

Imbalances in proteolytic activity have been linked to the development of inflammatory bowel diseases (IBD) and experimental colitis. Proteases in the intestine play important roles in maintaining homeostasis, but exposure of mucosal tissues to excess proteolytic activity can promote pathology through protease-activated receptors (PARs). Previous research implicates microbial proteases in IBD, but the underlying pathways and specific interactions between microbes and PARs remain unclear. In this study, we investigated the role of microbial proteolytic activation of the external domain of PAR2 in intestinal injury using mice expressing PAR2 with a mutated N-terminal external domain that is resistant to canonical activation by proteolytic cleavage. Our findings demonstrate the key role of proteolytic cleavage of the PAR2 external domain in promoting intestinal permeability and inflammation during colitis. In wild-type mice expressing protease-sensitive PAR2, excessive inflammation leads to the expansion of bacterial taxa that cleave the external domain of PAR2, exacerbating colitis severity. In contrast, mice expressing mutated protease-resistant PAR2 exhibit attenuated colitis severity and do not experience the same proteolytic bacterial expansion. Colonization of wild-type mice with proteolytic PAR2-activating Enterococcus and Staphylococcus worsens colitis severity. Our study identifies a previously unknown interaction between proteolytic bacterial communities, which are shaped by inflammation, and the external domain of PAR2 in colitis. The findings should encourage new therapeutic developments for IBD by targeting excessive PAR2 cleavage by bacterial proteases.

Keywords: DSS-induced colitis; Inflammatory bowel disease; colitis; gnotobiotic mice; inflammation; microbiota; protease-activated receptor 2 (PAR2); proteases; proteolytic activity.

MeSH terms

  • Animals
  • Bacteria / classification
  • Bacteria / enzymology
  • Bacteria / genetics
  • Bacteria / metabolism
  • Colitis* / metabolism
  • Colitis* / microbiology
  • Colitis* / pathology
  • Disease Models, Animal
  • Enterococcus / genetics
  • Enterococcus / metabolism
  • Gastrointestinal Microbiome
  • Humans
  • Inflammation / metabolism
  • Inflammation / microbiology
  • Inflammatory Bowel Diseases / metabolism
  • Inflammatory Bowel Diseases / microbiology
  • Inflammatory Bowel Diseases / pathology
  • Intestinal Mucosa / metabolism
  • Intestinal Mucosa / microbiology
  • Intestinal Mucosa / pathology
  • Mice
  • Mice, Inbred C57BL
  • Protein Domains
  • Proteolysis*
  • Receptor, PAR-2* / genetics
  • Receptor, PAR-2* / metabolism

Substances

  • Receptor, PAR-2
  • F2rl1 protein, mouse

Grants and funding

This study was funded by a Canadian Institutes of Health Research (CIHR) Project Grant [202010PJT] and by a Grants-In-Aid Crohn’s and Colitis Canada (CCC) grant to AC, who also holds the Paul Douglas Chair in Intestinal Research. LER holds a Doctoral Scholarship from CIHR and a graduate scholarship from the Farncombe Family Digestive Health Research Institute. This work was also supported by grants from the European Research Council [ERC-PIPE-310973] to NV and the French Ministry of Research and Technology, the National Agency for Research [ANR JCJC-11JSV1 001 01] to CD. PB holds the Richard Hunt AstraZeneca Chair in Gastroenterology. WR is supported by the German Research Foundation [Project Number 318346496, SFB1292/2 TP02]. HJG and EFV are supported by a CIHR Project Grant [PJT-183881]. EFV holds a Tier 1 Canada Research Chair in Microbial Therapeutics and Nutrition in Gastroenterology.